PRESS RELEASE published on 01/31/2024 at 18:09, 2 years 7 months ago AltaThera Pharmaceuticals at AF Symposium 2024 AltaThera Pharmaceuticals will present data on Sotalol IV, a treatment that may significantly shorten hospital stays for heart-related illnesses at the 29th Annual AF Symposium in Boston from February 1-3. The presentation will feature insights from the PEAKS Registry by Dr. T. Jared Bunch, an esteemed figure in the field of electrophysiology AF Symposium Electrophysiology AltaThera Pharmaceuticals Sotalol IV Hospital Stays
Published on 09/12/2026 at 02:35, 11 hours 18 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 53 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 48 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 28 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 53 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 23 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 38 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 43 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 8 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 38 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report